CanFite Biopharma (CANF)
(Delayed Data from AMEX)
$2.36 USD
0.00 (0.00%)
Updated May 31, 2024 03:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Brokerage Reports
0 items in cart
Can-Fite Biopharma Ltd [CANF]
Reports for Purchase
Showing records 61 - 80 ( 216 total )
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Advancement in COVID-19 Evaluates Piclidenoson?s Antiinflammatory and Antiviral Properties; Reiterate Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Namodenoson?s Nascent Value Positioned to Advance in 2021; Reiterate Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
BUY Rated: COMFORT Advances (Psoriasis) while Acrobat Falls
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
IDMC Recommendation to Continue Phase 3 Looks Positive for Piclidenoson in Psoriasis; Reiterate Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
BUY Rated: COMFORT Advances (Psoriasis) while Acrobat Falls (RA Stops)
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
2Q20 Update Shows Clinical Programs Positioned to Deliver; Reiterate Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Piclidenoson Edges Closer to Pilot Trial as COVID-19 Treatment; Reiterate Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
BUY Rated: Raises Capital at $2.0 for $3.4M - OK
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
BUY Rated: Raises Capital at $2.0 for $3.4M - OK
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Final Data Analysis From Namodenoson Phase 2 NASH Study Is Convincing of an Anti-Steatotic Effect
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
BUY Rated; Reports 1Q20 Results and Catalysts
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
BUY Rated; Reports 1Q20 Results and Catalysts
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
BUY Rated; Phase 2 Liver Fat Results Getting Better and Better
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Pre-IND Submitted to Discuss Piclidenoson for COVID-19; Reit Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Piclidenoson as a COVID-19 Play Has Strong Rationale; Reit Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V